English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

HMG-hCG therapy was performed on 109 patients who had previously received various forms of treatment but had failed to ovulate or become pregnant. From among the 109 patients, 80 (73.4%) succeeded in ovulation and 37 (33.9%) became pregnant. Ten patients with high FSH and low estrogen levels before the therapy failed to ovulate and were believed to have amenorrhea of ovarian origin. This indicated the importance of measurements of gonadotropin and estrogen prior to therapy with exclusion of patients in whom hMG-hCG therapy is expected not to be effective. Signs of ovarian hyperstimulation syndrome, such as ovarian enlargement, ascites and hydrothorax, were seen in 58% of 245 treated cycles. Our study revealed that there was remarkable increase in the levels of estrogen and progesterone in the majority of patients who presented clinical signs of ovarian hyperstimulation. indicating superovulation as the main cause of ovarian hyperstimulation syndrome which was confirmed at operation.

Induction of ovulation with human menopausal gonadotropin; with special reference to ovarian hyperstimulation syndrome and hormone excretion.